Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Business has been booming for the company, a multispecialty telehealth platform, with rapid growth in its weight loss offering, including compounded GLP-1 injection products. Hims & Hers expects ...

Feb 24 (Reuters) - Hims & Hers (HIMS.N), opens new tab said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk (NOVOb.CO), opens new ...

Hims & Hers (HIMS ... dosing,” Hims & Hers CEO Andrew Dudum told investors during a call on Monday evening. Instead, the company will focus on weight-loss pills and a generic version of ...

Hims & Hers said it expects between $2.3 billion and $2.4 billion in revenue this year. The company added that it expects its weight loss offerings to generate at least $725 million in revenue ...

Hims & Hers’ weight loss offerings will now mainly include its oral medications and the liraglutide injection, which the company plans to launch in the early second half of 2025. Also ...

Hims and Hers plans to stop selling compounded weight loss drugs after an FDA update. Hims and Hers' stock fell over 19% in after-hours trading on Monday. The FDA removed semaglutide injections ...